Ducord market seen growing as stem cell therapies gain ground

The Ducord market is expected to expand through 2035 as demand rises for stem cell treatments, cord blood banking and regenerative medicine. North America led the market in 2025, while Asia-Pacific is projected to grow fastest as healthcare investment and awareness increase.

Why it matters: - Ducord, a stem cell therapy derived from umbilical cord blood, is becoming more relevant as blood disorders rise and transplant medicine advances. - Market growth could affect research funding, cord blood banking, clinical adoption and access to alternative stem cell sources.

What happened: - The Business Research Company released its Ducord Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Ducord market is positioned for significant development as stem cell therapies reshape treatment options for blood-related disorders and other conditions. - The company made a free sample report available here. - The full report is available here.

The details: - Ducord is used mainly in hematopoietic stem cell transplantation. - Ducord helps regenerate the blood and immune systems for patients with hematopoietic disorders or those undergoing intense myeloablative treatment. - The report cites several growth drivers from the historical period, including the need for alternative stem cell sources, transplant medicine advances, donor scarcity, cord blood bank growth and better cryopreservation techniques. - The report expects additional support from rising funding for stem cell research, improved transplant success rates, broader use of regenerative therapies, greater awareness of cord blood benefits and continued healthcare infrastructure development. - Key forecast-period trends include wider use of cord blood stem cell therapies, more hematopoietic transplant procedures, growth in regenerative medicine applications, stronger cord blood banking networks and innovations in cell processing technologies. - The report links market expansion to the rising prevalence of blood disorders such as anemia, hemophilia, sickle cell disease and clotting abnormalities. - The Centers for Disease Control and Prevention reported in April 2024 that anemia accounted for 2.8 million physician office visits in the US, 6,021 deaths and a mortality rate of 1.8 deaths per 100,000 population. - The report also points to higher healthcare spending as a growth driver because it can support research, development and clinical testing. - The Office for National Statistics said UK healthcare spending rose 5.6% from 2022 to 2023 to about $317.63 billion (£292 billion). - Demand for minimally invasive procedures is another factor supporting the market. - The report says Ducord-related devices such as catheters, endoscopes and diagnostic tools support minimally invasive surgeries by reducing patient discomfort and improving outcomes. - The British Association of Aesthetic Plastic Surgeons reported a 5% increase in cosmetic surgical procedures from 2023 to 2024, with 27,462 procedures performed in 2024. - North America held the largest Ducord market share in 2025. - The Asia-Pacific region is projected to grow fastest during the forecast period. - The report also includes Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report frames Ducord as part of a broader shift toward cell-based and regenerative treatments, not just a niche transplant product. - The regional split suggests mature markets will lead current adoption, while faster growth may come from countries building out healthcare infrastructure and investing more in stem cell research.

What's next: - The market outlook depends on whether transplant success rates, research funding and banking networks continue to improve. - Adoption may accelerate if clinical use broadens beyond current hematopoietic applications and if awareness of cord blood benefits increases. - The company invited readers to contact its expert team for more information.